Skip to main content
SpringerLink
Log in

Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Boring CC, Squires TS, Tong T: Cancer Statistics, 1991 CA: A Journal for Clinicians 41:19–51, 1991

    Google Scholar 

  2. Perez CA, Fair WR, Ihde DC: Carcinoma of the Prostate In: Cancer: Principles and Practice of Oncology, Third Edition, DeVita VT, Hellman S, Rosenburg S (eds) 1989, pp. 1023–1058

  3. Grindey GB, Boder GB, Grossman CS, Howbert JJ, Poore GA, Shaw WN, Todd GC, Worzalla JF: Further development of diarylsulfonylureas as novel anti-cancer drugs. Proc Am Assoc Cancer Res 28:1224, 1987

    Google Scholar 

  4. Houghton JA, Houghton PJ: Human drug sensitivity testingin vitro. In: Hill BP, Dendy PP (eds) The xenograft as an intermediate model system. San Diego CA Academic, 1983, pp. 179–200

    Google Scholar 

  5. Thakar JH, Chapin C, Berg RH, Ashmun RA, Houghton PJ: Effect of antitumor diarylsulfonylureas onin vivo andin vitro mitochondrial structure and function. Cancer Res 51:6286–6291, 1991

    Google Scholar 

  6. Taylor CW, Alberts DS, Ketcham MA, Satterlee WG, Holdsworth MIT, Plezia PM, Peng YM, McCloskey TM, Roe DJ, Hamilton M, Salmon SE: Clinical Pharmacology of a novel diarylsulfonylurea anticancer agent. J Clin Oncol 7:1733–1740 1989

    Google Scholar 

  7. Hainsworth JD, Hande KR, Satterlee WG, Kuttesch J, Johnson DH, Grindey G, Jackson LE, Greco FA: Phase I clinical study of N-[(4-chlorophenyl) amino] carbonyl-2, 3-dihydro-1H-indene-5-sulfonamide (LY186641). Cancer Res 49:5217–5220, 1989

    Google Scholar 

  8. Neubauer BL, Merriman RL, Best KL, Goode RL, Sarosdy MF, Tanzer LR, Howbert JJ: Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984. J Urology 147:500–504, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center and the Wm. S. Middleton VA Hospital, Madison, Wisconsin

    George Wilding

  2. Lilly Research Laboratories, Eli Lilly Corporation, Indianapolis, IN

    Gerald Grindey & David Seitz

  3. Division of Hematology-Oncology, Department of Medicine, Indiana University Medical Center Indianapolis, IN, USA

    Nikhil Munshi & Lawrence Einhorn

Authors
  1. George Wilding
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerald Grindey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nikhil Munshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Seitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lawrence Einhorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilding, G., Grindey, G., Munshi, N. et al. Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer. Invest New Drugs 11, 203–205 (1993). https://doi.org/10.1007/BF00874156

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00874156

Keywords

Search

Navigation